Roivant Sciences Ltd. (ROIV) · Sep 8, 2026 · Other events

Roivant’s mosliciguat clears Phase 2 with huge PH-ILD efficacy, now faces Phase 3

Above the bar — PVR reduction of 56.3% plus statistically significant 6MWD and NT-proBNP wins

Roivant’s mosliciguat beat the clinical bar across PVR, walking distance and cardiac biomarkers. Phase 3 enrollment is already underway.

The timing was expected; the magnitude was the surprise. Roivant had already flagged PHocus topline data for the second half of 2026, so the existence of this catalyst was not new. But there was no clean published efficacy consensus to anchor against; the relevant test was whether the study cleared its clinical success bar. It did, across the primary endpoint and both key secondary endpoints.

The Phase 2 result was broad rather than a single-endpoint win. At Week 16, mosliciguat produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, with p<0.0001. 〔0〕 It also improved walking distance while reducing a cardiac-stress biomarker, making the result more credible than a purely hemodynamic readout.

MeasurePHocus resultComparison / significance
PVR at Week 16-56.3% placebo-adjustedMosliciguat -51.3% vs. placebo +6.6%; p<0.0001 (Primary endpoint)
6MWD at Week 16+35.2 meters placebo-adjustedMosliciguat +20.3m vs. placebo -14.9m; p=0.0027 (Secondary endpoint)
NT-proBNP at Week 16-357.7 pg/mL; -53.2%p=0.0002 (Secondary endpoint)
6MWD at Week 24+52.7 meters placebo-adjustedNominal p<0.0001 (Exploratory)
NT-proBNP at Week 24-487.1 pg/mL; -75.9%Nominal p<0.0001 (Exploratory)
Cough incidence12.1% mosliciguat vs. 18.2% placeboFavorable tolerability comparison

The durability signal strengthens the read, although Week 24 is exploratory. Treatment effects continued to improve through the placebo-controlled period, with the walking-distance benefit reaching 52.7 meters and NT-proBNP falling 75.9% versus baseline on a placebo-adjusted basis. That supports the company's chronic-dosing thesis, but the exploratory designation means the Week 16 endpoints carry the core evidentiary weight.

The filing materially de-risks mosliciguat but does not establish approval or commercial success. Phase 3 PHrontier has begun and is designed to enroll approximately 375 patients, moving the program directly into confirmatory testing. 〔1〕 The remaining risk is therefore not whether PHocus produced a signal—it clearly did—but whether the effect reproduces in a larger study and translates into regulatory and commercial value. Net, this is an above-the-bar clinical readout and a meaningful upgrade to the mosliciguat program.

What to watch next

PHrontier Phase 3 enrollment and topline results

Original filing on SEC EDGAR

More Roivant Sciences Ltd. news

Roivant’s mosliciguat clears Phase 2 with huge PH-ILD efficacy, now faces Phase 3 | ROIV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.